Plozasiran durably cuts triglycerides, pancreatitis risk in severe hypertriglyceridemia

MUNICH — In patients with severe hypertriglyceridemia, plozasiran was well-tolerated, reduced triglycerides by up to 81% and prevented acute pancreatitis events compared with placebo, a speaker reported.“Severe hypertriglyceridemia is probably one of the largest gaps in the management of lipid disorders. Above 5 mmol/L is a gateway for all sorts of conditions that preventative